

**FEETME**

## FeetMe announces the closing of a seed round

Paris, 18th September, 2017 - FeetMe, a medical device company that produces smart and connected insoles for improved running, walking and gait analysis, today announced it has raised € 1.95 million in seed funding. The investment round was led by Kurma Diagnostics, with additional investment from the new Paris Saclay seed fund, Idinvest Partners, Seventure and SOS Ventures (a current shareholder of FeetMe).

The innovative technology from FeetMe allows gait and posture analysis in real-time and real-life conditions. The technology combines pressure sensors, motion sensors and learning algorithms to analyse patients' functional capacity, as well as empower rehabilitation among sufferers of gait disorders.

100 million people worldwide suffer from gait disorders. Gait disorders are often a forerunner and indicator of evolutive diseases: multiple sclerosis, Parkinson disease, fragility among elderly, peripheral neuropathies and diabetic foot problems. Quantifying disease status and progression can be a real challenge for both physicians and patients without real life data. Today only subjective tools such as clinical scales exist to quantify and qualify mobility, lacking sensitivity to help adapting therapeutic treatments.

Alexis Mathieu, founder and CEO at FeetMe said: "This seed round will help us pursue the development of our product to target therapeutics areas in collaboration with market players " announces. "The connected insole allows patient and physician to manage and evaluate in real time and remotely treatments efficacy to adapt them more precisely and without constraints for the patient. Creating new digital biomarkers will reinforce existing therapeutics with companion diagnostic and monitoring solution"

### **About FeetMe :**

FeetMe is a certified medical device company developing movement analysis solutions based on connected insoles.  
[www.feetme.fr](http://www.feetme.fr)

### **About Kurma Partners :**

Founded in July 2009, Kurma Partners is a key European player in the financing of Innovation in Healthcare and Biotechnology, from pre-seed to growth capital, notably through Kurma Biofund I, II, and Kurma Diagnostics, as well as via strategic partnerships with prestigious European research and medical institutions.  
[www.kurmapartners.com](http://www.kurmapartners.com)

### **About Paris-Saclay Seed Fund :**

The Paris Saclay Seed Fund was launched by Université Paris-Saclay and its members and operations were entrusted to two Venture Capital funds. : Partech Ventures, a leading investor in technology and digital, and Kurma Partners, which leads investment in life sciences. This fund will invest 50 million euros.  
[www.seedfund.parissaclay.com](http://www.seedfund.parissaclay.com)

### **About Idinvest Partners :**

Idinvest Partners is a European leader in financing small and medium-sized enterprises, whose mission



is to fund European businesses at various stages of growth. With more than €8 billion under management, Idinvest Partners can harness a range of complementary expertise to help businesses grow quickly using equity and private debt investment, both directly and via private equity funds. Since its formation in 1997, Idinvest has financed more than 3,500 European businesses through its three business lines: Venture & Growth Capital, Private Debt and Private Funds Group.  
[www.idinvest.com](http://www.idinvest.com)

#### About Seventure :

With over €660m in assets under management as of the end of 2016, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in two fields: Digital technologies in France and Germany, and Life sciences across Europe, Israel and North America.

In Life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology, and last but not least: the Microbiome, nutrition, foodtech and personalized medicine. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. Recently, Seventure Partners successfully launched Health for Life Capital™ which has attracted strategic investments from prestigious organizations including Danone, Tereos, Tornier, Lesaffre, Bel and Novartis, as well as entrepreneurs and financial institutions.

Seventure is a subsidiary of Natixis Global Asset Management. Natixis is the international corporate, investment, insurance and financial services arm of Groupe BPCE, the second- largest banking group in France.


For more details: [www.seventure.com](http://www.seventure.com) / Twitter @SeventureP Plus d'informations sur la société :

#### About SOSV :

With 300M USD under management SOSV has funded over 600 startups. SOSV currently invests into over 150 startups per year through its accelerator programs focused on a few key areas: HAX (hardware and connected devices), IndieBio (synthetic biology), Chinaccelerator & MOX (cross-border internet) and Food-X (food).

[www.sosv.com](http://www.sosv.com)

#### Images :



#### Contact :

Alexis Mathieu

Co-fondateur et CEO

**mobile:** + 33 (0) 6 70 62 02 08 (FR)

**email:** [alexis.mathieu@feetme.fr](mailto:alexis.mathieu@feetme.fr)

**site web:** [www.feetme.fr](http://www.feetme.fr) **twitter:** @Feet\_Me

**adresse:** 157 bd MacDonald 75019 Paris